Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00287820 · ClinicalTrials.gov registry record · Phase 4

Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism

A Phase 4 study of Diabetes and Schizophrenia, sponsored by Nathan Kline Institute for Psychiatric Research.

Completed
Registry status
Phase 4
Development phase
46
Enrollment target
1
Study location

NCT00287820: Completed Phase 4 study of Diabetes and Schizophrenia, sponsored by Nathan Kline Institute for Psychiatric Research.

NCT00287820 is a Phase 4 study of Diabetes and Schizophrenia that has completed, run by Nathan Kline Institute for Psychiatric Research. The registered enrollment target is 46 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00287820, a Phase 4 study of Diabetes and Schizophrenia, has completed, sponsored by Nathan Kline Institute for Psychiatric Research.

COMPLETED
Registry status
Phase 4
Development phase
46 participants
Enrollment target
1
Study location

Study Summary

The primary objective of the study is to assess whether chronic treatment with olanzapine over a five-month period produces a significant increase in abnormalities in glucose levels. The main secondary objective is to evaluate whether the increase in glucose levels and rate of glucose abnormalities differs between Olanzapine and Risperidone during this treatment period. Additional secondary objectives of the study are to investigate similar questions with respect to glycohemoglobin, triglycerides and other measures of glucose and lipid metabolism. We hypothesize that Olanzapine will not be inferior to Risperidone in extent of increase in the primary outcome measure of serum glucose, and secondary measures of glycohemoglobin, insulin and lipids.

Interventions

  • DRUG Olanzapine
  • DRUG risperidone
  • DRUG olanzapine

Study Locations (1)

New York

  • Manhattan Psychaitric Center - New York

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2004-02
Est. Completion 2007-09
Phase Phase 4

What the finished NCT00287820 record still lists

NCT00287820 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (98% lower).

The record links to 4 conditions, with Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Olanzapine is the first listed.

NCT00287820 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00287820 about?

NCT00287820 is a clinical study titled "Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism". The primary objective of the study is to assess whether chronic treatment with olanzapine over a five-month period produces a significant increase in abnormalities in glucose levels. The main secondary objective is to evaluate whether the increase in glucose levels and rate of glucose abnormalities ...

What is the current status of trial NCT00287820?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2004-02. Estimated completion is 2007-09.

What conditions does trial NCT00287820 study?

This clinical trial studies the following conditions: Diabetes, Schizophrenia, Metabolic Syndrome, Hyperglycemia.

What interventions are being tested in trial NCT00287820?

The interventions under investigation include: Olanzapine (DRUG), risperidone (DRUG), olanzapine (DRUG).

Who is sponsoring clinical trial NCT00287820?

This trial is sponsored by Nathan Kline Institute for Psychiatric Research, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00287820 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00287820's enrollment target sits among peer trials

46 256th of 338 higher than 83 of 338 other Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01890590 · 46 participants · NA

    A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

  • NCT03191149 · 46 participants · Phase 2

    Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • NCT03510208 · 46 participants · Phase 1

    Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

  • NCT04048278 · 46 participants · Early Phase 1

    Lidocaine Infusion in Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00287820, the US trial registry maintained by the National Library of Medicine. NCT00287820 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.